{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:37:53Z","timestamp":1787168273846,"version":"build-2736575974"},"reference-count":36,"publisher":"Royal College of General Practitioners","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BJGP Open"],"accepted":{"date-parts":[[2025,7,8]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adherence to oral bisphosphonates for osteoporosis is poor; the challenges and complexity of follow-up reviews in general practice are implicated as a contributory cause. Clinical pharmacists in general practice are an expanding professional group within the UK NHS workforce and could provide person-centred medicines optimisation interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To explore clinician and patient perceptions towards a pharmacist-led osteoporosis review, including identifying current practice, care gaps, and implementation barriers and facilitators.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design &amp; setting<\/jats:title>\n                    <jats:p>Qualitative interview study with patients, clinical pharmacists, GPs, osteoporosis specialists, and service commissioners.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Semi-structured interviews were transcribed verbatim and analysed thematically, informed by a normalisation process theory approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 32 participants were interviewed in 22 one-to-one interviews and four small group interviews. Three themes relevant to the design and implementation of a pharmacist-led osteoporosis follow-up review were identified: dissonant views among patients and healthcare professionals about current provision and needs; pharmacists' suitability for, and role in, osteoporosis care and training needs; and contextual issues affecting implementation of a new pharmacist-led osteoporosis review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study found that current practice with respect to following-up patients initiated on oral bisphosphonate treatment in primary care is variable. Although pharmacists were highlighted as well-placed to conduct osteoporosis reviews, varying views about the need for this were highlighted along with a number of contextual barriers, including lack of financial and policy drivers in primary care, workload challenges, varying pharmacist skills and autonomy, and lack of coordination across the health system.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3399\/bjgpo.2025.0093","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T15:10:15Z","timestamp":1763133015000},"page":"BJGPO.2025.0093","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacist-led osteoporosis review: perceptions of current practice, care gaps, and implementation challenges"],"prefix":"10.3399","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3316-1412","authenticated-orcid":false,"given":"Andrew","family":"Sturrock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0309-2890","authenticated-orcid":false,"given":"Meaghan","family":"Grabrovaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurna","family":"Bullock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma M","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy L","family":"Finch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shona","family":"Haining","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby","family":"Helliwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Horne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Maidment","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Monk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Pryor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Statham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Paskins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Turnbull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"McKinley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1987","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"2026081911351720000_10.2.BJGPO.2025.0093.1","unstructured":"International Osteoporosis Foundation (2022) Scorecard for Osteoporosis in Europe (SCOPE): epidemiology, burden and treatment of osteoporosis in the United Kingdom. accessed. https:\/\/www.osteoporosis.foundation\/sites\/iofbonehealth\/files\/scope-2021\/UK%20report.pdf. 18 Mar 2026."},{"key":"2026081911351720000_10.2.BJGPO.2025.0093.2","unstructured":"International Osteoporosis Foundation (2025) Report series and number, Broken Bones, Broken Lives: a roadmap to solve the fragility fracture crisis in the United Kingdom. accessed. https:\/\/www.osteoporosis.foundation\/educational-hub\/files\/broken-bones-broken-lives-roadmap-solve-fragility-fracture-crisis-united. 10 Jun 2026."},{"key":"2026081911351720000_10.2.BJGPO.2025.0093.3","unstructured":"National Institute for Health and Care Excellence (NICE) (2017) Bisphosphonates for treating osteoporosis [Technology appraisal guidance TA464]. accessed. https:\/\/www.nice.org.uk\/guidance\/ta464. 18 Mar 2026."},{"key":"2026081911351720000_10.2.BJGPO.2025.0093.4","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-019-05104-5"},{"key":"2026081911351720000_10.2.BJGPO.2025.0093.5","unstructured":"NICE (2025) Scenario: management. accessed. https:\/\/cks.nice.org.uk\/topics\/osteoporosis-prevention-of-fragility-fractures\/management\/management\/#:~:text=For%20people%20whose%20fracture%20risk%20is%20below%20the,use%20the%20intervention%20thresholds%20to%20guide%20treatment%20decisions. 18 Mar 2026."},{"key":"2026081911351720000_10.2.BJGPO.2025.0093.6","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-020-00766-9"},{"key":"2026081911351720000_10.2.BJGPO.2025.0093.7","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-022-06453-4"},{"key":"2026081911351720000_10.2.BJGPO.2025.0093.8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083552"},{"key":"2026081911351720000_10.2.BJGPO.2025.0093.9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-085323"},{"key":"2026081911351720000_10.2.BJGPO.2025.0093.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2020.09.010"},{"key":"2026081911351720000_10.2.BJGPO.2025.0093.11","doi-asserted-by":"publisher","DOI":"10.1080\/08870446.2022.2144923"},{"key":"2026081911351720000_10.2.BJGPO.2025.0093.12","doi-asserted-by":"publisher","DOI":"10.3310\/hsdr08260"},{"key":"2026081911351720000_10.2.BJGPO.2025.0093.13","doi-asserted-by":"publisher","DOI":"10.3399\/BJGP.2024.0562"},{"key":"2026081911351720000_10.2.BJGPO.2025.0093.14","doi-asserted-by":"publisher","DOI":"10.3399\/BJGP.2023.0145"},{"key":"2026081911351720000_10.2.BJGPO.2025.0093.15","doi-asserted-by":"publisher","DOI":"10.3310\/nihropenres.13766.1"},{"key":"2026081911351720000_10.2.BJGPO.2025.0093.16","unstructured":"General Pharmaceutical Council (2021) Standards for the initial education and training of pharmacists, accessed. https:\/\/www.pharmacyregulation.org\/students-and-trainees\/education-and-training-providers\/standards-education-and-training-pharmacists. 19 Mar 2026."},{"key":"2026081911351720000_10.2.BJGPO.2025.0093.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2021.10.006"},{"key":"2026081911351720000_10.2.BJGPO.2025.0093.18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-048811"},{"key":"2026081911351720000_10.2.BJGPO.2025.0093.19","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-4-29"},{"key":"2026081911351720000_10.2.BJGPO.2025.0093.20","doi-asserted-by":"publisher","DOI":"10.1080\/14780887.2020.1769238"},{"key":"2026081911351720000_10.2.BJGPO.2025.0093.21","unstructured":"NHS England (2025) Primary care networks. accessed. https:\/\/www.england.nhs.uk\/primary-care\/primary-care-networks\/. 19 Mar 2026."},{"key":"2026081911351720000_10.2.BJGPO.2025.0093.22","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8295.1992.tb02426.x"},{"key":"2026081911351720000_10.2.BJGPO.2025.0093.23","doi-asserted-by":"publisher","DOI":"10.1093\/intqhc\/mzm042"},{"key":"2026081911351720000_10.2.BJGPO.2025.0093.24","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15722"},{"key":"2026081911351720000_10.2.BJGPO.2025.0093.25","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15325"},{"key":"2026081911351720000_10.2.BJGPO.2025.0093.26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-081934"},{"key":"2026081911351720000_10.2.BJGPO.2025.0093.27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0309729"},{"key":"2026081911351720000_10.2.BJGPO.2025.0093.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2016.08.005"},{"key":"2026081911351720000_10.2.BJGPO.2025.0093.29","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp21X717485"},{"key":"2026081911351720000_10.2.BJGPO.2025.0093.30","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-023-01586-w"},{"key":"2026081911351720000_10.2.BJGPO.2025.0093.31","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X18785539"},{"key":"2026081911351720000_10.2.BJGPO.2025.0093.32","doi-asserted-by":"publisher","DOI":"10.37901\/jcphp16-00032"},{"key":"2026081911351720000_10.2.BJGPO.2025.0093.33","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-014-2659-8"},{"key":"2026081911351720000_10.2.BJGPO.2025.0093.34","doi-asserted-by":"publisher","DOI":"10.3399\/BJGP.2024.0320"},{"key":"2026081911351720000_10.2.BJGPO.2025.0093.35","doi-asserted-by":"publisher","DOI":"10.3399\/BJGPO.2023.0221"},{"key":"2026081911351720000_10.2.BJGPO.2025.0093.36","doi-asserted-by":"publisher","DOI":"10.3399\/BJGP.2024.0190"}],"container-title":["BJGP Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3399\/BJGPO.2025.0093","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:35:56Z","timestamp":1787164556000},"score":1,"resource":{"primary":{"URL":"http:\/\/bjgpopen.org\/lookup\/doi\/10.3399\/BJGPO.2025.0093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,8,19]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.3399\/BJGPO.2025.0093"],"URL":"https:\/\/doi.org\/10.3399\/bjgpo.2025.0093","relation":{},"ISSN":["2398-3795"],"issn-type":[{"value":"2398-3795","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]}}}